A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä

Stroma AReactive invasion Front Areas (SARIFA) in early-stage oral tongue squamous cell carcinoma



Tekijät: Almangush, Alhadi; Faisal, Muhammad; Haglund, Caj; Kowalski, Luiz Paulo; Hagström, Jaana; Coletta, Ricardo D.; Mäkitie, Antti A.; Salo, Tuula; Leivo, Ilmo

Julkaisuvuosi: 2026

Lehti: Oral Oncology

Artikkelin numero: 107936

Vuosikerta: 176

ISSN: 1368-8375

eISSN: 1879-0593

DOI: https://doi.org/10.1016/j.oraloncology.2026.107936

Julkaisun avoimuus kirjaamishetkellä: Avoimesti saatavilla

Julkaisukanavan avoimuus : Osittain avoin julkaisukanava

Verkko-osoite: https://doi.org/10.1016/j.oraloncology.2026.107936

Rinnakkaistallenteen osoite: https://research.utu.fi/converis/portal/detail/Publication/516251971

Rinnakkaistallenteen lisenssi: CC BY

Rinnakkaistallennetun julkaisun versio: Kustantajan versio


Tiivistelmä
Background

Stroma AReactive Invasion Front Areas (SARIFA) has recently been introduced as a prognostic indicator. The prognostic value of SARIFA has not been studied in early-stage oral tongue squamous cell carcinoma (OTSCC).

Material and methods

A total of 287 cases of early-stage OTSCC were included in this multicenter study. SARIFA was defined as direct contact between tumor cells and the adipose tissue, and was assessed in hematoxylin and eosin (HE)-stained sections.

Results

In early-stage OTSCC, SARIFA-positive tumors were associated with worse disease-specific survival with a hazard ratio (HR) of 1.86 (95% CI 1.06–3.28, P = 0.032), overall survival (HR 1.52, 95% CI 1.06–2.19, P = 0.023) and disease-free survival (HR 1.79, 95% CI 1.09–2.93, P = 0.021).

Conclusions

SARIFA is a histomorphology-based prognosticator, that can identify cases with early-stage OTSCC who might benefit from a multimodality treatment protocol.


Ladattava julkaisu

This is an electronic reprint of the original article.
This reprint may differ from the original in pagination and typographic detail. Please cite the original version.

Julkaisussa olevat rahoitustiedot: 
This research has been funded by The Finnish Cancer Society, Turku University Hospital Fund, Finska Läkaresällskapet, Maritza and Reino Salonen Foundation and the Sigrid Jusélius Foundation.


Last updated on